The candidate drug, developed in Italy in the L’Aquila laboratories of the Biopharmaceutical Group, finds its origins in the research of Nobel Prize winner Rita Levi Montalcini.
Neurotrophic keratitis is a rare disease that affects less than 1 in 5,000 people in the world and for which there are currently no targeted therapies.
The REPARO study is ongoing in 39 centers in 9 European countries and seeks to evaluate the safety and effectiveness of rhNGF.
Both the FDA and the European regulatory agency, the EMA [European Medicines Agency], had already assigned rhNGF the status of orphan drug for the treatment of retinitis pigmentosa, another ophthalmic disease that is currently incurable.
Dompe, one of the leading biopharmaceutical companies in Italy that is also present in the U.S. through its New Yorksubsidiary, is committed to developing innovative therapies for other rare and orphan diseases in Diabetology, Organ Transplants, and Oncology.
July 23, 2014
Dompe, a leader in R&D for new therapeutic solutions for the treatment of rare diseases, announces that rhNGF (Recombinant Human Nerve Growth Factor) has been designated as an orphan drug by the American Food and Drug Administration (FDA).
The candidate drug, developed by the research of Dompe, has been designated as an orphan drug for the treatment of neurotrophic keratitis, a degenerative corneal disease that affects less than 1 in 5,000 people1 and is currently without a cure. This is the second orphan drug designation by the FDA for rhNGF, after the recent designation for the treatment of retinitis pigmentosa, a rare genetic disease that affects more than 1 million people worldwide2.
This acknowledgment represents an important step in the clinical development of the drug, which is currently in advanced stages of experimentation for the treatment of neurotrophic keratitis in the REPARO study. The randomized, double-blind study includes 39 centers in 9 European countries (Italy, Great Britain, Germany, France, Belgium, Spain, Portugal, Poland, Hungary) and involves patients suffering from unilateral neurotrophic keratitis with grade 2 lesions (persistent epithelial defect) or grade 3 lesions (corneal ulcers) that do not respond to the currently available medical treatment. The objective of the trial is to evaluate the safety, tolerability, and effectiveness of two different doses of recombinant human nerve growth factor (rhNGF) compared to the placebo. The more than 170 patients enrolled in the study are divided into three different groups, treated respectively with two different doses of rhNGF and with the placebo. The secondary objectives include the evaluation of corneal lesion healing, improvement in visual acuity, and the sensitivity of the cornea.
“We are particularly proud of this new FDA designation, which represents an important recognition of our Research & Development efforts in the field of ophthalmology on a global scale, particularly in North America,” – explains Eugenio Aringhieri, CEO of the Dompe Group. “It is another confirmation of the constant dialogue with the international regulatory agencies in order to bring health issues that still need to be resolved to the forefront as well as possible therapeutic solutions for diseases that are currently without a cure. This is the direction that the efforts of our Group is taking, focused on the identification of innovative drugs to protect patients around the world.”
rhNGF is the result of a specific research project at the Dompe Center for Research & Development of l’Aquila and is produced using recombinant DNA technology, or by transferring human genetic material into bacterial DNA, enabling the bacteria to produce NGF that is entirely identical to that naturally produced by the human body.
rhNGF, the Recombinant Human Nerve Growth Factor developed by Dompe, is identical to the protein that is naturally produced by the body and promotes the development and survival of nerve cells, including those of the retina. NGF (Nerve Growth Factor) was discovered by Rita Levi Montalcini, who was awarded the Nobel Prize in Physiology or Medicine in 1986. The protein stimulates the growth, maintenance, and survival of nerve cells, in addition to the cells of the cornea and the retina. The cornea in particular has a particularly dense innervation, approximately 400 times denser than that of the skin. Treatment with rhNGF-based ophthalmic solution aims to restore the innervation of the corneal area that has been compromised by the disease in order to promote recovery of visual function. In the future, rhNGF may also prove useful in other forms of optic neuropathies, as it has for retinitis pigmentosa in the treatment of glaucoma and dry eye syndrome due to its innovative mechanism of action.
Neurotrophic keratitis is a rare serious degenerative disease of the eye, for which there is currently no cure, characterized by progressive damage to the cornea that can lead to corneal perforation, with consequent loss of vision. It can be caused by various clinical ocular conditions such as herpetic corneal infections (herpes zoster and simplex), eye surgeries, misuse of topical medications, use of contact lenses, and even systemic conditions such as diabetes or vitamin A deficiency. It affects less than 1 in 5,000 people in the world.
Dompe is one of the top biopharmaceutical companies in Italy, focused on the development of innovative pharmaceutical solutions for diseases with high social impact, which are often incurable. Based out of Italy, Dompe has its headquarters inMilan and focuses its research efforts in areas with unmet therapeutic needs, such as diabetes, organ transplants, ophthalmology, and oncology. The industrial center in L’Aquila (Abruzzo) houses a biotechnology facility known worldwide for its excellence and develops Primary Care drugs intended for markets in 30 countries worldwide. In 2013, Dompe opened a subsidiary in the United States.
For more information: www.dompe.com
Forward looking statements
This press release makes reference to certain information that may not coincide with expected future results. Dompe firmly believes in the soundness and reasonableness of the concepts expressed. However, some of the information is subject to a certain degree of uncertainty in relation to its research and development activities and the necessary verifications to be performed by regulators. Therefore, as of today, Dompe cannot guarantee that the expected results will be consistent with the information provided above.
1 Sacchetti M., Lambiase A., Diagnosis and management of neurotrophic keratitis. Clinical Ophthalmology 2014; 8: 571–579.
2 Source: Anasagasti A, Irigoyen C, Barandika O et al., Current mutation discovery approaches in retinitis pigmentosa, Vision Res. 2012; 75: 117-129.